AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25493968 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation plus daily sedation interruption
Number of subjects: 430
Study 25493968 — intervention group
Group type: COMPARATOR
Intervention: Protocolized sedation
Number of subjects: 430
Study 25493968 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium screening positive patients
Number of subjects: 430
Study 25493968 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirious patients
Number of subjects: 430
Study 25493968 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent factors associated with delirium onset
Number of subjects: 430
Study 23319256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 245
Study 23319256 — intervention group
Group type: COMPARATOR
Intervention: 3D conformal radiotherapy (3DCRT)
Number of subjects: 245
Study 21995376 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum for 3 months (from months 6 to 9)
Number of subjects: 248
Study 18555546 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated whole brain irradiation (40 Gy in 20 fractions of 2 Gy twice daily)
Number of subjects: 90
Study 18555546 — intervention group
Group type: COMPARATOR
Intervention: Conventional whole brain irradiation (20 Gy in 5 daily fractions)
Number of subjects: 90
Study 15990738 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) infusion
Number of subjects: 1044
Study 15990738 — intervention group
Group type: COMPARATOR
Intervention: No infusion (control)
Number of subjects: 1044
Study 14504153 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 ml of mepivacaine 10 mg x ml(‐1)
Number of subjects: 114
Study 14504153 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 ml of mepivacaine 10 mg x ml(‐1)
Number of subjects: 114
Study 14504153 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of mepivacaine 10 mg x ml(‐1)
Number of subjects: 114
Study 10389555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine and hyaluronidase 75 units/ml
Number of subjects: 100
Study 10389555 — intervention group
Group type: COMPARATOR
Intervention: 1:1 mixture of 2% lignocaine and 0.5% bupivacaine and hyaluronidase 75 units/ml
Number of subjects: 100
Study 8906404 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic perceptual memory retrieval
Number of subjects: 0
Study 8906404 — intervention group
Group type: EXPERIMENTAL
Intervention: Recollective memory retrieval
Number of subjects: 0
Study 8906404 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-declarative memory retrieval
Number of subjects: 0
Study 8906404 — intervention group
Group type: EXPERIMENTAL
Intervention: Rote-declarative memory retrieval
Number of subjects: 0
Study 8906404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-declarative memory retrieval
Number of subjects: 0
Study 8906404 — intervention group
Group type: COMPARATOR
Intervention: Semantic memory retrieval
Number of subjects: 0
Study 8906404 — intervention group
Group type: COMPARATOR
Intervention: Motor skill memory retrieval
Number of subjects: 0
Study 8906404 — intervention group
Group type: COMPARATOR
Intervention: Rote skill memory retrieval
Number of subjects: 0
Study 8906404 — intervention group
Group type: COMPARATOR
Intervention: Cognitive skill memory retrieval
Number of subjects: 0
Study 1867082 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose treatment with trimethoprim
Number of subjects: 100
Study 1867082 — intervention group
Group type: COMPARATOR
Intervention: 5-day course treatment with trimethoprim
Number of subjects: 100
Study 6125193 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 0
Study 6125193 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg)
Number of subjects: 0
Study 6125193 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg)
Number of subjects: 0
Study 29199193 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality program using Armeo® spring for 45 min three times/week for 12 weeks
Number of subjects: 40
Study 29199193 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy program
Number of subjects: 40
Study 25647753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 24329850 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 42
Study 24329850 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study 23106658 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (2500 ova, 3 weekly doses over 6 months)
Number of subjects: 89
Study 23106658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 23106658 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Number of subjects: 89
Study 19715417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg 3 times daily for 5 days)
Number of subjects: 615
Study 19715417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 17559753 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadolor (200 mg, test formulation)
Number of subjects: 48
Study 17559753 — intervention group
Group type: COMPARATOR
Intervention: Ultram ER (200 mg, reference formulation)
Number of subjects: 48
Study 15124243 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR 20
Number of subjects: 6
Study 15124243 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR 50
Number of subjects: 6
Study 15124243 — intervention group
Group type: EXPERIMENTAL
Intervention: Average number of ACR criteria met at 50% level
Number of subjects: 6
Study 15124243 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve of ACR criteria met
Number of subjects: 6
Study 12038917 — intervention group
Group type: EXPERIMENTAL
Intervention: Low reporting quality trials (median score, 9 [range, 3.5-10.5])
Number of subjects: 60
Study 12038917 — intervention group
Group type: EXPERIMENTAL
Intervention: High reporting quality trials (median score, 18 [range 16.5-22.0])
Number of subjects: 60
Study 12038917 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 60
Study 12038917 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment analyses
Number of subjects: 60
Study 9533973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine or Doxepin
Number of subjects: 14
Study 9533973 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponse group (Fluoxetine or Doxepin)
Number of subjects: 14
Study 9533973 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 14
Study 7898332 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise 45 min.d-1, 5 d.wk-1, for 12 wk
Number of subjects: 100
Study 2796855 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, doxorubicin and prednisone (VAP), consolidation therapy with 6‐thioguanine, cytosine arabinoside (TA) and cyclophosphamide/vincristine/cytosine arabinoside/prednisone (COAP), and maintenance therapy of alternating TA and COAP with or without VAP pulses.
Number of subjects: 0
Study 872608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 21
Study 872608 — intervention group
Group type: COMPARATOR
Intervention: Senna
Number of subjects: 21
Study 31541495 — intervention group
Group type: EXPERIMENTAL
Intervention: New HPV infection with normal to low-grade cytology
Number of subjects: 379
Study 31239021 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month behavioral weight loss (BWL) intervention
Number of subjects: 99
Study 28521717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral regimens (specific regimens not detailed)
Number of subjects: 1771
Study 25993906 — intervention group
Group type: EXPERIMENTAL
Intervention: Local trial - inhalation of a hypercapnic gas mixture (5% CO2 in air) for 5 minutes with open circulation to active calf muscle, followed by PECO.
Number of subjects: 0
Study 25993906 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic trial - circulation through the muscle closed throughout exercise and PECO phases during hypercapnic gas inhalation.
Number of subjects: 0
Study 25993906 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia trial - inhalation of a hyperoxic hypercapnic gas mixture (95% O2 and 5% CO2) for 1 minute during PECO under systemic conditions.
Number of subjects: 0
Study 25993906 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Local and Systemic trials.
Number of subjects: 0
Study 25993906 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Systemic and Hyperoxia trials.
Number of subjects: 0
Study 23881421 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed extract (100 mg capsules three times daily)
Number of subjects: 30
Study 23881421 — intervention group
Group type: COMPARATOR
Intervention: Control (no GSE)
Number of subjects: 30
Study 21814146 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation (3 billion colony forming units/day for 21 days)
Number of subjects: 61
Study 21814146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 21814146 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) supplementation
Number of subjects: 61
Study 19489894 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAF program participation
Number of subjects: 641
Study 19489894 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 641
Study 16956622 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity (AS)
Number of subjects: 404
Study 15028823 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of alendronate daily for 10 years
Number of subjects: 247
Study 15028823 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of alendronate daily
Number of subjects: 247
Study 15028823 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of alendronate
Number of subjects: 247
Study 15028823 — intervention group
Group type: COMPARATOR
Intervention: Placebo after discontinuation
Number of subjects: 247
Study 12572052 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether combined with primaquine (Group A: orally, Group B: intramuscularly)
Number of subjects: 121
Study 12572052 — intervention group
Group type: COMPARATOR
Intervention: Single artemether (Group C: orally, Group D: intramuscularly)
Number of subjects: 121
Study 9124619 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 25
Study 9124619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8129541 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg SL
Number of subjects: 20
Study 8129541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg SL
Number of subjects: 20
Study 3083459 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg/70 kg
Number of subjects: 0
Study 3083459 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg/70 kg
Number of subjects: 0
Study 3083459 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg/70 kg
Number of subjects: 0
Study 3083459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31571403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50 mg/d plus solifenacin 5 mg/d
Number of subjects: 647
Study 31571403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50 mg/d plus propiverine 20 mg/d
Number of subjects: 647
Study 31571403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50 mg/d plus imidafenacin 0.2 mg/d
Number of subjects: 647
Study 31571403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50 mg/d plus tolterodine 4 mg/d
Number of subjects: 647
Study 31571403 — intervention group
Group type: COMPARATOR
Intervention: All groups (including mirabegron 50 mg once daily during screening)
Number of subjects: 647
Study 29435899 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain placement
Number of subjects: 5013
Study 26395781 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with general therapy
Number of subjects: 0
Study 26395781 — intervention group
Group type: COMPARATOR
Intervention: General therapy (antibiotics only)
Number of subjects: 0
Study 24942709 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/d)
Number of subjects: 126
Study 24942709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 22166162 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulfate (CS)
Number of subjects: 31
Study 22166162 — intervention group
Group type: COMPARATOR
Intervention: Freeze-dried bone allograft (FDBA)
Number of subjects: 31
Study 20378678 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Training + Balance program (FT+B)
Number of subjects: 43
Study 20378678 — intervention group
Group type: COMPARATOR
Intervention: Functional Training program (FT)
Number of subjects: 43
Study 18340272 — intervention group
Group type: COMPARATOR
Intervention: Electric stimuli delivered to the right median nerve (Con 1)
Number of subjects: 0
Study 18340272 — intervention group
Group type: COMPARATOR
Intervention: Auditory stimuli delivered to both ears (Con 2)
Number of subjects: 0
Study 18340272 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric and subsequent auditory stimuli (Con 3)
Number of subjects: 0
Study 18340272 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimuli delivered to the bilateral median nerve (Con 4)
Number of subjects: 0
Study 15795210 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing gloves at 20-minute intervals or prior to cementation
Number of subjects: 50
Study 15795210 — intervention group
Group type: COMPARATOR
Intervention: Changing gloves prior to cementation
Number of subjects: 50
Study 12351954 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins excluding A
Number of subjects: 1078
Study 12351954 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 1078
Study 12351954 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 1078
Study 10064647 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sandwich anesthetic (PSAND)
Number of subjects: 120
Study 10064647 — intervention group
Group type: EXPERIMENTAL
Intervention: Total propofol anesthesia (TPROP)
Number of subjects: 120
Study 10064647 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia (INHAL)
Number of subjects: 120
Study 7769295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine adjuvanted with alum
Number of subjects: 20
Study 7769295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine adjuvanted with alum plus 3-deacylated monophosphoryl lipid A (MPL)
Number of subjects: 20
Study 7769295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (alum and alum-MPL)
Number of subjects: 20
Study 7769295 — intervention group
Group type: EXPERIMENTAL
Intervention: MPL
Number of subjects: 20
Study 7769295 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected subjects
Number of subjects: 20
Study 7769295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 protected subject
Number of subjects: 20
Study 2284521 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole pessaries (500 mg, once daily for 7 days)
Number of subjects: 75
Study 2284521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 94616 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg per day
Number of subjects: 20
Study 94616 — intervention group
Group type: COMPARATOR
Intervention: Moduretic (50 mg hydrochlorothiazide and 5 mg amiloride)
Number of subjects: 20
Study 94616 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 20
Study 6195479 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG after 1 g of oral aspirin pretreatment
Number of subjects: 7
Study 6195479 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG after 8 days of aspirin, 500 mg every 48 h
Number of subjects: 7
Study 6195479 — intervention group
Group type: COMPARATOR
Intervention: NTG without aspirin pretreatment
Number of subjects: 7
Study 31138568 — intervention group
Group type: EXPERIMENTAL
Intervention: ASN100 (combination of ASN‐1 and ASN‐2) at 3,600 or 8,000 mg
Number of subjects: 52
Study 31138568 — intervention group
Group type: EXPERIMENTAL
Intervention: ASN100 (combination of ASN‐1 and ASN‐2)
Number of subjects: 52
Study 31138568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31138568 — intervention group
Group type: EXPERIMENTAL
Intervention: ASN‐1 or ASN‐2 at 200, 600, 1,800, or 4,000 mg
Number of subjects: 52
Study 31138568 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label ASN100 at 3,600 or 8,000 mg
Number of subjects: 52
Study 29563100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi (12 or 24 weeks, once or twice weekly)
Number of subjects: 226
Study 29563100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi (24 weeks, twice weekly)
Number of subjects: 226
Study 29563100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi (24 weeks)
Number of subjects: 226
Study 29563100 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (24 weeks, twice weekly)
Number of subjects: 226
Study 29563100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi (various groups)
Number of subjects: 226
Study 26909531 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally based exercise (Bhangra dance)
Number of subjects: 75
Study 26909531 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard exercise (gym‐based)
Number of subjects: 75
Study 26909531 — intervention group
Group type: COMPARATOR
Intervention: Control (nonexercise)
Number of subjects: 75
Study 25287629 — intervention group
Group type: EXPERIMENTAL
Intervention: E-RS (EXACT - Respiratory Symptoms) scale
Number of subjects: 1581
Study 22377744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline at daily doses of 200, 300, 400, 600, and 800 mg for periods of 2‐10 months
Number of subjects: 23
Study 19833819 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Carboplatin (GC)
Number of subjects: 1135
Study 19833819 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Paclitaxel (GP)
Number of subjects: 1135
Study 19833819 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel + Carboplatin (PC)
Number of subjects: 1135
Study 18055944 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride plus needs-focused intervention
Number of subjects: 124
Study 18055944 — intervention group
Group type: COMPARATOR
Intervention: Needs-focused intervention without amisulpride
Number of subjects: 124
Study 16131623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal detection task with auditory signal (1000-Hz tone) and visual signal (asterisk)
Number of subjects: 0
Study 16131623 — intervention group
Group type: COMPARATOR
Intervention: Bimodal detection task
Number of subjects: 0
Study 11861971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpyrifos (CPF) administered orally at doses of 0.5-100 mg/kg in rats and 0.5-2 mg/kg in humans.
Number of subjects: 2
Study 11861971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpyrifos (CPF)
Number of subjects: 2
Study 9435424 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP‐1 (100-micrograms i.v. bolus)
Number of subjects: 68
Study 7823066 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 243
Study 7823066 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 243
Study 7823066 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 243
Study 7823066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 243
Study 7823066 — intervention group
Group type: COMPARATOR
Intervention: All drugs
Number of subjects: 243
Study 1977464 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg bd
Number of subjects: 120
Study 1977464 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg bd
Number of subjects: 120
Study 1977464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 40798 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 10, 40 or 50 mg
Number of subjects: 12
Study 40798 — intervention group
Group type: EXPERIMENTAL
Intervention: alprenolol 200 mg
Number of subjects: 12
Study 40798 — intervention group
Group type: COMPARATOR
Intervention: no beta-blockade (control)
Number of subjects: 12
Study 31671219 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers associated with increased ESCC risk (FGF19, ST1A1, STAMBP, AXIN1, CASP8, NT3, CD6, CDCP1, CD5, SLAMF1, OPG, CSF1)
Number of subjects: 476
Study 31671219 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers inversely associated with ESCC risk (CXCL6, CCL23, CXCL5, TGFA, CXCL1, OSM, CCL4)
Number of subjects: 476
Study 31671219 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant biomarkers (FGF19, CASP8, STAMBP, ST1A1, CCL-4)
Number of subjects: 476
Study 31671219 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation among biomarkers (CASP8, STAMBP, ST1A1)
Number of subjects: 476
Study 30970113 — intervention group
Group type: EXPERIMENTAL
Intervention: X technique (6 repetitions)
Number of subjects: 30
Study 30970113 — intervention group
Group type: EXPERIMENTAL
Intervention: X technique (3 repetitions)
Number of subjects: 30
Study 30970113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systematized guidelines)
Number of subjects: 30
Study 28283805 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention (eight sessions)
Number of subjects: 74
Study 25734979 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 month screener based on Bayley Scales of Infant Development II
Number of subjects: 0
Study 25031380 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion device
Number of subjects: 40
Study 25031380 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy
Number of subjects: 40
Study 22914044 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB
Number of subjects: 153
Study 22914044 — intervention group
Group type: COMPARATOR
Intervention: CWC
Number of subjects: 153
Study 22914044 — intervention group
Group type: COMPARATOR
Intervention: PCA
Number of subjects: 153
Study 19785568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 857